Abpro Holdings (ABP) Q1 2026 earnings summary

Executive summary

• Focused on developing next-generation antibody therapeutics in immuno-oncology, ophthalmology, and infectious disease, with lead candidates ABP-102 and ABP-201 in preclinical/early clinical stages.

• Completed a 1-for-30 reverse stock split effective October 31, 2025, and merged with Atlantic Coastal Acquisition Corp. II in November 2024.

• Delisted from Nasdaq in February 2026 due to non-compliance with listing standards; now trades on OTC Pink Limited Market.

Financial highlights

• Net loss for Q1 2026 was $1.0 million, a 74% improvement from $3.9 million in Q1 2025, driven by reduced R&D and G&A expenses.

• Operating expenses decreased 68% year-over-year to $0.9 million, with R&D down 96% and G&A down 65%.

• No revenue generated in Q1 2026 or Q1 2025; accumulated deficit reached $120.0 million as of March 31, 2026.

• Cash and restricted cash totaled $5.4 million at quarter-end, up from $1.4 million a year prior, mainly due to $7.3 million raised via equity issuance.

Outlook and guidance

• Expects continued operating losses and negative cash flows as product candidates advance.

• Management concluded there is substantial doubt about the ability to continue as a going concern within one year without additional capital.

• Plans to seek further funding through equity, debt, collaborations, and grants; may delay or reduce programs if funding is insufficient.